Changes in tumor-associated lymphocytes (e.g., CD3+, CD4+, and CD8+), upregulation of INF-gamma stimulated genes in tumor transcripts, and increase in chemokines (e.g., CXCL9 and CXCL10) were observed, while no significant change in PD-L1 expression under nivolumab treatment was reported [48]. This evidence concerns the gene CD8A and neoplasm.